menu
    • menu
    [{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Levocept","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Sebela Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Sebela Pharmaceuticals \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Sebela Pharmaceuticals \/ PRA Health Sciences"},{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"BRAINTREE LABS","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sebela Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sebela Pharmaceuticals \/ Sebela Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sebela Pharmaceuticals \/ Sebela Pharmaceuticals"},{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sebela Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sebela Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sebela Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"Destiny Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2023","type":"Collaboration","leadProduct":"NTCD-M3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sebela Pharmaceuticals","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Liquid","sponsorNew":"Sebela Pharmaceuticals \/ Sebela Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sebela Pharmaceuticals \/ Sebela Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Sebela Pharmaceuticals

    Menu

    Sebela Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sebela Reports Positive Phase 3 TRIUMpH Results for Tegoprazan in GERD

                            Details : BLI5100 (tegoprazan) is a novel agent and member of a class of oral medications known as P-CABs. It is being evaluated in late-stage clinical trial studies for the treatment of GERD.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 23, 2025

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Destiny Pharma

                            Deal Size : $570.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Agreement with Sebela Pharmaceuticals for NTCD-M3

                            Details : Under the terms of the deal, Sebela will lead the future clinical development and commercialisation activities of NTCD-M3 in North America. NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. di...

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : $1.0 million

                            February 24, 2023

                            Lead Product(s) : NTCD-M3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Destiny Pharma

                            Deal Size : $570.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : BRAINTREE LABS

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U....

                            Details : Tegoprazan (CJ-12420) is a novel agent in development for the treatment of acid-related gastrointestinal diseases. Tegoprazan has already received marketing authorization in multiple territories, including South Korea and China.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : BRAINTREE LABS

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levocept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : PRA Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 07, 2020

                            Lead Product(s) : Levocept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : PRA Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veracept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 24, 2018

                            Lead Product(s) : Veracept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veracept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 16, 2018

                            Lead Product(s) : Veracept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Sebela Pharmaceuticals

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levocept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Efficacy and Safety of LevoCept

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 29, 2016

                            Lead Product(s) : Levocept

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth